UBC & THREAD Partner in Decentralized Research
UBC has announced their selection of THREAD for decentralized approaches across studies in the UBC portfolio. The fully connected offering further enables decentralized approaches and a more integrated offering from data acquisition through actionable insights in a single platform.
UBC’s virtual evidence generation offeiring combined with THREAD’s platform and services, enable organizations to conduct DCTs globally with tools that include eConsent, eCOA, sensors, devices, telehealth, and engaging patients that participate in UBC programs. UBC’s existing offering includes digital recruitment and engagement strategies, in-home nursing support, clinical assessments, and drug administration, as well as powerful real-world data infrastructure, data enrichment strategies, and more.
For more information, click here.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
